Overview
Effect of CP-778,875 on HDL-C in Subjects With Abnormal Lipid Levels and Type 2 Diabetes.
Status:
Completed
Completed
Trial end date:
2007-06-01
2007-06-01
Target enrollment:
0
0
Participant gender:
All
All
Summary
To assess the effect of CP-778,875 on HDL-C cholesterol in adult subjects with dyslipidemia and type 2 diabetesPhase:
Phase 2Accepts Healthy Volunteers?
NoDetails
Lead Sponsor:
Pfizer
Criteria
Inclusion Criteria:- HDL-C < or = 45 mg/dL for men and < or = 55 mg/dL for women
- Triglycerides between 150-500 mg/dL
- Fasting Plasma Glucose 140-240 mg/dL
Exclusion Criteria:
- Known cardiovascular, carotid, or peripheral vascular disease